Study
Nicotinamide Riboside May Improve Vascular and Cognitive Health in Seniors with PAD
A study suggests that nicotinamide riboside supplementation might enhance blood vessel function and cognitive performance in older adults with peripheral artery disease.
Summary
In plain language
Recent research explored how nicotinamide riboside (NR), a vitamin supplement, could benefit older adults with peripheral artery disease (PAD). The study found that taking NR for four weeks seemed to improve blood vessel health and cognitive abilities. Peripheral artery disease affects many seniors, causing poor circulation and increasing the risk of cognitive decline. The findings suggest that NR supplementation could offer a new way to support vascular and brain health for seniors dealing with PAD. While promising, these results come from a small trial and further research is needed to confirm the benefits. Seniors interested in this supplement should consult their healthcare provider.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study was a small, open-label clinical trial involving eight older adults with peripheral artery disease, focusing on the effects of nicotinamide riboside (NR) supplementation over four weeks.
The researchers observed improvements in blood vessel function and cognitive performance, along with reduced oxidative stress in participants.
The study was limited by its small size and short duration, meaning larger and longer trials are necessary to validate these findings.
For seniors, these results suggest that NR could be a valuable addition to managing vascular and cognitive health, though more evidence is needed.
Seniors should discuss with healthcare providers before starting new supplements like NR.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Nicotinamide Riboside May Improve Vascular and Cognitive Health in Seniors with PAD
Published October 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored October 22, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study is a single-arm pilot trial with no control group, limiting its design score. Bias control is minimal due to lack of randomization and blinding. Statistical methods are standard but lack power analysis. Transparency is moderate with adherence to STROBE but no pre-registration. Conflicts of interest are present due to industry funding. The study is relevant to the target population of seniors. Journal quality is unassessed due to unspecified publication.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 3.3/10 | |
| Bias control | 0.0/10 | |
| Statistical methods | 5.0/10 | |
| Reporting completeness | 5.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 10.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This pilot study investigates the effects of nicotinamide riboside supplementation on vascular and cognitive health in older adults with peripheral artery disease. It reports improvements in endothelial function and cognitive performance after a 4-week intervention.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Conditions This Research Covers
These condition pages help connect the paper back to the real-world health concerns it addresses.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.